Zydus Worldwide DMCC Acquires Assertio Holdings for $166.4 Million

Zydus Worldwide DMCC, a unit of Zydus Lifesciences Limited, has announced the acquisition of pharmaceutical firm Assertio Holdings for approximately $166.4 million in an all-cash transaction. This acquisition is notable as it highlights Zydus's strategic expansion into the differentiated pharmaceutical product space, particularly in oncology, where Assertio has a substantial focus.

The terms of the acquisition involve Zydus purchasing all outstanding shares of Assertio common stock at $23.50 per share. This offer delivers a 30.6% premium over an earlier agreement Assertio had with Garda Therapeutics and a 75.8% premium over Assertio's stock price as of March 20, 2026. The Board of Directors at Assertio, after a strategic review and considering competing acquisition proposals, deemed Zydus's proposal the most advantageous for their shareholders, thereby terminating the prior agreement with Garda.

Assertio’s Board Chair, Heather Mason, emphasized the confidence in choosing Zydus, highlighting the offer's strong overall value, lack of financing contingencies, and certainty in transaction execution. The deal will be executed through a tender offer, with Zydus subsequently merging Assertio's remaining shares into the acquisition at the agreed price of $23.50 per share. The companies anticipate finalizing the transaction in the second quarter of 2026, contingent on the tender of a majority of outstanding shares. No regulatory approvals are expected to be necessary, smoothing the path to completion.

For Zydus, the acquisition represents a significant move in the pharmaceutical sector, expanding its footprint in the specialized market for oncology products. As competition intensifies in this space, securing Assertio's differentiated product lines could potentially bolster Zydus's market position, offering a strategic advantage over its competitors.

Upon completion, Assertio will delist from the Nasdaq Stock Market, ending its run as an independent entity amidst a consolidating pharmaceutical landscape. The success of this acquisition will be closely watched, both for its strategic merits and as a bellwether of ongoing consolidation trends in the industry.